Beam Therapeutics Elects New Directors
Investors affirm executive compensation and reappoint Deloitte as auditor, signaling strong support.
June 09, 2025

Beam Therapeutics Gains Shareholder Approval Across All Proposals at Annual Meeting
On June 4, Beam Therapeutics held its 2025 annual meeting and received a strong show of support from investors. Every proposal on the agenda passed—clearing the way for leadership continuity and ongoing execution of the company’s strategy.
Board of Directors: New Class II Members Elected
Shareholders elected three Class II directors who will serve through 2028: Dr. Mark Fishman, Dr. Carole Ho, and Kathleen Walsh. All three secured broad approval. Dr. Fishman received about 62 million votes, while Dr. Ho and Ms. Walsh each received over 71 million. Around 12 million broker non-votes were recorded, but they didn’t affect the outcome.
These appointments lock in a board with deep expertise in biotech and governance—key as Beam continues moving its pipeline forward.
Deloitte Reappointed as Auditor
Shareholders also ratified Deloitte & Touche LLP to remain Beam’s independent public accounting firm for 2025. The vote wasn’t close—more than 84 million shares backed the decision. Just over 200,000 voted against or abstained.
This means Beam’s financial oversight stays in familiar hands, keeping the company on steady footing during its next phase of growth.
Executive Compensation Approved
Investors gave the thumbs up to Beam’s executive pay program in a non-binding vote. About 71.7 million shares voted in favor, with less than 600,000 opposed. A small number abstained, and broker non-votes came in at the same level as other proposals.
The outcome points to investor confidence in how Beam aligns leadership incentives with company performance.
What This Signals
The voting results reflect a clear message: shareholders are on board with Beam’s leadership, financial approach, and long-term direction. With its board re-elected, executive compensation supported, and auditors locked in, Beam is set to keep moving forward without disruption.
Share
Read More Articles